Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HIV-MAG DNA vaccine + GENEVAX IL-12 + VSV-Gag boost
- Development stage
- Unknown
- Lead developer
- Aurobindo Pharma
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Electroporation
01
Overview
The HIV-MAG DNA vaccine regimen is an experimental heterologous prime-boost HIV vaccine strategy. It consists of a multivalent DNA vaccine (HIV-MAG) encoding multiple HIV-1 antigens (Gag, Pol, Env, Nef, Tat, and Vif) co-administered with a plasmid DNA adjuvant (GENEVAX IL-12) encoding human interleukin-12. The DNA components are delivered intramuscularly via the TriGrid Delivery System, which utilizes electroporation to enhance cellular uptake and immunogenicity. This priming phase is followed by a viral vector boost using a recombinant vesicular stomatitis virus (VSV) expressing the HIV-1 Gag protein (VSV-Gag). Developed through a collaboration between Profectus BioSciences, Ichor Medical Systems, and NIAID, the regimen aims to elicit robust and broad cellular and humoral immune responses against HIV-1.
- Brand names
- TriGrid
- Other names
- HIV-MAG DNA vaccine + IL-12 plasmid + VSV boostHIV-MAG DNA vaccine + interleukin-12 plasmid DNA + vesicular stomatitis virus boost
02
Targets
HIV-1 Pol polyproteinVif (HIV-1 Vif)Tat (HIV-1 Tat)Nef (HIV-1 Nef)Gag (HIV-1 Gag polyprotein)
Beyond the preview
Go deeper on HIV-MAG DNA vaccine + GENEVAX IL-12 + VSV-Gag boost.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HIV-MAG DNA vaccine + GENEVAX IL-12 + VSV-Gag boost.